SCHEMBL14697392

SCHEMBL14697392

O=c1c2ccccc2nc(S)n1-c1ccc(F)c(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.49
▸ TP53 P04637 1/20 0.49
▸ PHOSPHO1 Q8TCT1 1/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ MAPT P10636 3/20 0.47
▸ ABCG2 Q9UNQ0 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ POLB P06746 1/20 0.46
▸ MEN1 O00255 2/20 0.45
▸ GAA P10253 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ CYP1A2 P05177 1/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ CYP2D6 P10635 1/20 0.45
▸ CYP2C9 P11712 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14697276 0.90 GRM1 (0.52) LMNATP53SMN1; SMN2MAPTL3MBTL1
SCHEMBL14697075 0.88 SMN1; SMN2 (0.56) LMNATP53SMN1; SMN2MAPTL3MBTL1
SCHEMBL14697079 0.88 L3MBTL1 (0.49) LMNATP53SMN1; SMN2MAPTL3MBTL1
SCHEMBL13747380 0.84 SMN1; SMN2 (0.60) LMNATP53SMN1; SMN2MEN1GAA
SCHEMBL14697359 0.84 L3MBTL1 (0.47) LMNATP53SMN1; SMN2MAPTL3MBTL1
SCHEMBL9670704 0.80 HPGD (0.61) LMNATP53PHOSPHO1SMN1; SMN2MAPT
SCHEMBL9670555 0.79 NPC1 (0.58) LMNASMN1; SMN2MAPTL3MBTL1POLB
SCHEMBL14697173 0.76 SMN1; SMN2 (0.40) TP53SMN1; SMN2MAPTRXFP1
SCHEMBL9671236 0.76 SMN1; SMN2 (0.50) SMN1; SMN2MEN1GAAKMT2AALDH1A1
SCHEMBL5028783 0.75 SMN1; SMN2 (0.66) LMNATP53SMN1; SMN2POLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10611733-B2 Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2020-04-07 — — US disclosed
US-20170144978-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SOUTHERN RESEARCH INSTITUTE 2017-05-25 — — US disclosed
US-20170144978-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SOUTHERN RESEARCH INSTITUTE 2017-05-25 — — US disclosed
US-20170144978-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SOUTHERN RESEARCH INSTITUTE 2017-05-25 — — US disclosed
US-9598402-B2 Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections SOUTHERN RESEARCH INSTITUTE (US) 2017-03-21 — — US disclosed
US-9598402-B2 Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections SOUTHERN RESEARCH INSTITUTE (US) 2017-03-21 — — US disclosed
US-9598402-B2 Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections SOUTHERN RESEARCH INSTITUTE (US) 2017-03-21 — — US disclosed
EP-2744787-B1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SOUTHERN RES INST (US) 2016-11-02 — — EP disclosed
EP-2744787-B1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SOUTHERN RES INST (US) 2016-11-02 — — EP disclosed
US-20140256753-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2014-09-11 — — US disclosed
US-20140256753-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2014-09-11 — — US disclosed
US-20140256753-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2014-09-11 — — US disclosed
EP-2744787-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS Southern Research Institute (US) 2014-06-25 — — EP disclosed
WO-2013025508-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SOUTHERN RESEARCH INSTITUTE (US) 2013-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256753-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS HAVCR2, EIF2AK2, GLS2 LMNA 2359/4885TP53 2385/4885PHOSPHO1 4505/4885
US-20170144978-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS ZC3HAV1, EIF2AK2, GTF3C3 LMNA 2862/4885TP53 2756/4885PHOSPHO1 4605/4885
US-10611733-B2 Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections ZC3HAV1, EIF2AK2, GTF3C3 LMNA 2862/4885TP53 2756/4885PHOSPHO1 4605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback